8-K: Medpace Reports Strong Q3 2025 Results, Raises Outlook

Medpace Holdings, Inc. announced robust third-quarter 2025 financial results, with significant revenue and net new business growth, and provided an optimistic full-year 2025 financial guidance.

Summary

• Third quarter 2025 revenue increased 23.7% to $659.9 million, compared to $533.3 million for the comparable prior-year period.
• Net new business awards were $789.6 million in the third quarter of 2025, an increase of 47.9% from $533.7 million in the comparable prior-year period, resulting in a net book-to-bill ratio of 1.20x.
• GAAP net income for the third quarter of 2025 was $111.1 million, or $3.86 per diluted share, compared to $96.4 million, or $3.01 per diluted share, for the third quarter of 2024.
• EBITDA for the third quarter of 2025 increased 24.9% to $148.4 million, or 22.5% of revenue, compared to $118.8 million, or 22.3% of revenue, for the comparable prior-year period.
• Backlog as of September 30, 2025, increased 2.5% to $3,000.6 million from $2,927.4 million as of September 30, 2024.
• Year-to-date 2025 revenue was $1,821.8 million, an increase of 15.9% from the comparable prior-year period.
• Year-to-date 2025 GAAP net income was $316.0 million, or $10.64 per diluted share, compared to $287.4 million, or $8.96 per diluted share, for the comparable prior-year period.
• Cash and cash equivalents were $285.4 million at September 30, 2025, and $246.2 million in cash flow from operating activities was generated during the third quarter of 2025.
• The company repurchased 14,649 shares for $4.5 million during the third quarter of 2025, and 2,961,924 shares for $912.9 million for the nine months ended September 30, 2025.
• As of September 30, 2025, $821.7 million remained under the authorized share repurchase program.
• Full-year 2025 revenue is forecasted in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024.
• Full-year 2025 GAAP net income is forecasted in the range of $431.0 million to $439.0 million, with diluted EPS in the range of $14.60 to $14.86.
• Full-year 2025 EBITDA is expected in the range of $545.0 million to $555.0 million.

Sentiment

Score: 9

Explanation: The company reported strong financial results across key metrics for Q3 2025, including significant revenue growth, a high book-to-bill ratio, and increased net income and EBITDA. The full-year 2025 guidance is optimistic, projecting continued substantial growth. The ongoing share repurchase program further enhances shareholder value. While net income margin slightly decreased, the overall performance and outlook are highly positive.

Positives

• Revenue for Q3 2025 increased significantly by 23.7% year-over-year to $659.9 million, demonstrating strong top-line growth.
• Net new business awards surged by 47.9% to $789.6 million in Q3 2025, indicating robust demand and future revenue potential.
• The net book-to-bill ratio of 1.20x for Q3 2025 highlights that new business awards are substantially exceeding revenue recognized.
• GAAP net income grew to $111.1 million, and diluted EPS increased to $3.86 per share in Q3 2025, reflecting improved profitability.
• EBITDA increased by 24.9% to $148.4 million in Q3 2025, with an improved EBITDA margin of 22.5%.
• Backlog grew by 2.5% to $3,000.6 million as of September 30, 2025, providing visibility into future revenue.
• Generated strong cash flow from operating activities of $246.2 million during Q3 2025.
• The company continues to execute its share repurchase program, having repurchased $912.9 million worth of shares year-to-date 2025, with $821.7 million remaining under authorization, which can enhance shareholder value.
• The full-year 2025 financial guidance projects continued strong growth, with revenue expected to increase by 17.6% to 20.0% and significant increases in GAAP net income and EBITDA.

Negatives

• Net income margin decreased to 16.8% in Q3 2025 from 18.1% in Q3 2024, indicating a slight compression in profitability relative to revenue.
• Cash and cash equivalents decreased from $669.4 million at December 31, 2024, to $285.4 million at September 30, 2025, primarily due to significant share repurchases.
• Interest income, net, declined substantially from $7.528 million in Q3 2024 to $1.517 million in Q3 2025.

Risks

• Potential loss, delay, or non-renewal of contracts, or non-payment by customers for services performed.
• Failure to convert backlog to revenue at present or historical conversion rates.
• Failure to maintain or generate new business awards.
• Fluctuation in financial results between fiscal quarters and years.
• Risks and uncertainties related to disruptions or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases.
• Decreased operating margins due to increased pricing pressure or other factors.
• Failure to perform services or operate the business in accordance with contractual requirements, government regulations, and ethical considerations.
• Impact of underpricing contracts, overrunning cost estimates, or failing to receive approval for or experiencing delays with documentation of change orders.
• Failure of third parties to provide critical support services.
• Failure to increase market share, grow the business, successfully execute growth strategies, or manage growth effectively.
• Impact of a failure to retain key executives or other personnel or recruit qualified personnel.
• Risks associated with information systems infrastructure, including potential cybersecurity breaches and other disruptions.
• Risks from use of machine learning and generative artificial intelligence (AI), including insufficient human oversight or lack of controls.
• Adverse results from customer or therapeutic area concentration.
• Risks associated with doing business internationally, including effects of tariffs and trade wars, and the Foreign Corrupt Practices Act.
• Future net losses and the impact of changes in tax laws and regulations.
• Failure to attract suitable investigators and patients to clinical trials.
• Liability risks associated with research and development services, including harm to patients, and inadequate insurance coverage.
• Fluctuations in exchange rates and general economic conditions, including inflation and international conflicts.
• Impact of a natural disaster or other catastrophic event.
• Negative outsourcing trends in the biopharmaceutical industry and a reduction in aggregate expenditures and research and development budgets.
• Inability to compete effectively with other Contract Research Organizations (CROs).
• Impact of healthcare reform and consolidation in the biopharmaceutical industry.
• Failure to comply with federal, state, and foreign healthcare laws and regulations regarding personal data protection.
• Impact of government shutdowns and potential involvement in costly intellectual property lawsuits.
• Actions by regulatory authorities or customers to limit the scope of indications related to or withdraw an approved drug, biologic, or medical device from the market.
• Impact of industry-wide reputational harm to CROs.

Future Outlook

Medpace forecasts full-year 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue. GAAP net income for 2025 is projected between $431.0 million and $439.0 million, with diluted earnings per share expected to be in the range of $14.60 to $14.86. Full-year 2025 EBITDA is anticipated to be between $545.0 million and $555.0 million. This guidance assumes a full-year 2025 tax rate of 18.25% to 18.75%, interest income of $12.2 million, and 29.5 million diluted weighted average shares outstanding, excluding the potential impact of any future share repurchases after September 30, 2025.

Industry Context

Medpace's strong third-quarter performance, characterized by significant revenue growth and a high book-to-bill ratio, indicates robust demand within the clinical research organization (CRO) sector. This suggests a healthy and expanding market for clinical development services across the biotechnology, pharmaceutical, and medical device industries. The company's ability to secure substantial new business awards and grow its backlog reflects its competitive strength and the ongoing need for specialized expertise in accelerating medical therapeutic development.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Stakeholder Impact

• Shareholders: Likely positive impact due to strong financial performance, increased earnings per share, and the ongoing share repurchase program, which signals confidence and returns capital.
• Employees: Continued growth and expansion, with approximately 6,200 employees across 44 countries, suggest stable to growing employment opportunities and potential for career advancement.
• Customers (biotechnology, pharmaceutical, medical device industries): Medpace's robust performance and high book-to-bill ratio indicate its continued capacity and expertise in providing high-quality clinical development services, ensuring reliable partnership.

Next Steps

• Medpace will host a conference call on Thursday, October 23, 2025, at 9:00 a.m. ET to discuss its third quarter 2025 results.
• A webcast replay of the call and a supplemental slide presentation will be available on the Investors section of Medpace's website.

Key Dates

Recommendation

Medpace demonstrated robust financial performance in Q3 2025, exceeding prior-year results across key metrics such as revenue, net new business awards, net income, and EBITDA. The strong book-to-bill ratio of 1.20x and increased backlog indicate sustained demand for its clinical research services. Furthermore, the company's optimistic full-year 2025 guidance, projecting significant growth in revenue and earnings, coupled with an active share repurchase program, suggests strong shareholder value creation and continued operational momentum. The company's position as a scientifically-driven, global CRO in a growing industry further supports a positive outlook.

Keywords

CRO, Clinical Research Organization, Biotechnology, Pharmaceutical, Medical Device, Financial Results, Q3 2025, Revenue, Net Income, EBITDA, Book-to-Bill, Backlog, Share Repurchase, Medpace, MEDP, Clinical Development